Table S1.
Characteristic | Shortly exposed, N=5,265 |
---|---|
Age (years) | 57 (46–67) |
Female, n (%) | 4,343 (82.5) |
“Start date” | Apr 2010 (Jan 2007–Sept 2012) |
Duration of follow-up after “start date” (days) | 1,476 (818–2,476) |
Time between the end of exposure and the end of follow-up (days) | 1,369 (697–2,371) |
Dosage (mg/day) | 399 (267–400) |
Duration of exposure (days) | 105 (30–210) |
Underlying diseases, n (%) | |
Rheumatoid arthritis | 3,938 (74.8) |
Systemic lupus erythematosus | 774 (14.7) |
Sjogren syndrome | 292 (5.5) |
Dermatomyositis/polymyositis | 5 (0.1) |
Other connective tissue diseasesa | 251 (4.8) |
Light eruption | 5 (0.1) |
Number of prescriptions ofb | |
Methotrexate | 0 (0–63) |
Azathioprine | 0 (0–1) |
Glucocorticoids | 1 (0–56) |
NSAIDs | 10 (0–98) |
Metformin | 0 (0–6) |
Vitamin D | 0 (0–37) |
Smoking status, n (%) | |
Nonsmokers | 2,551 (48.5) |
Ex-smokers | 1,589 (30.2) |
Smokers | 1,111 (21.1) |
Missing | 14 (0.3) |
Townsend deprivation index, n (%) | |
0 (less deprived) | 172 (3.3) |
1 | 1,383 (26.3) |
2 | 1,201 (22.8) |
3 | 1,111 (21.1) |
4 | 818 (15.5) |
5 (more deprived) | 535 (10.2) |
Missing | 45 (0.8) |
BMI (kg/m2) | 26.5 (23.2–30.9) |
Past history of, n (%) | |
Non-skin cancer | 236 (4.5) |
Hematological malignancy | 34 (0.6) |
Skin cancer | 189 (3.6) |
Hypertension | 1,330 (25.3) |
Diabetes | 427 (8.1) |
Incident outcomes after “start date”, n (%) | |
Non-skin cancer | |
Breast | 66 (1.3) |
Colon | 17 (0.3) |
Prostate | 9 (0.2) |
Lung | 39 (0.7) |
Other or nonspecific codes | 79 (1.5) |
Hematological malignancy | 42 (0.8) |
Skin cancer | 129 (2.5) |
Metastasis | 41 (0.8) |
Death | 380 (7.2) |
Notes:
Systemic sclerosis, antiphospholipid syndrome, mixed and undifferentiated connective tissue diseases.
Before the date of cancer or a randomly selected date for those without cancer. Continuous variables are reported as medians and interquartile range except for the number of medication prescriptions that are reported as medians and 5th–95th percentile range.